Journal article · 2025 · Open access

Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities

Sheng Yang, Yen‐Nhi Ngoc Ta, Yunching Chen

Drug Delivery and Translational Research, 15(11), 4067–4097 · Published 8 July 2025 · DOI 10.1007/s13346-025-01908-7

Open PDFView at the publisherCite this paper

In brief

“Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities” is a 2025 journal article by Sheng Yang and 2 co-authors, published in Drug Delivery and Translational Research. OpenAlex counts 19 citations as of 21 November 2026, which puts it in the top 2% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Drug Delivery and Translational Research.

Citations
19
Most cited in
2026 (13)
Field-weighted impact
6.26
References
164
Authors
3

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal five-year survival rate. The tumor microenvironment, characterized by dense stroma and immunosuppression, significantly limits the effectiveness of current treatments, including immunotherapy. Nanotechnology offers a promising solution by enabling precise drug delivery, enhancing immune activation, and overcoming physical barriers within the tumor microenvironment. In this review, we explore the mechanisms of PDAC development and the immunosuppressive nature of its tumor microenvironment, emphasizing the challenges faced by immunotherapy. We also examine the role of nanotechnology in modulating the tumor microenvironment, enhancing cancer vaccine efficacy, and stimulating immune cells within the PDAC tumor microenvironment. Current clinical trials employing nanotechnology-based strategies are discussed, providing insight into their potential for improving therapeutic outcomes. While significant challenges remain in translating nanomedicine into clinical success, the integration of nanotechnology with immunotherapy holds promise for overcoming the limitations of conventional treatments and improving survival in PDAC patients.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Yang, S., Ta, Y. N., & Chen, Y. (2025). Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities. Drug Delivery and Translational Research, 15(11), 4067–4097. https://doi.org/10.1007/s13346-025-01908-7

MLA 9

Yang, Sheng, et al. “Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities.” Drug Delivery and Translational Research, vol. 15, no. 11, 2025, pp. 4067–4097. https://doi.org/10.1007/s13346-025-01908-7.

Chicago

Yang, Sheng, Yen‐Nhi Ngoc Ta, and Yunching Chen. 2025. “Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities.” Drug Delivery and Translational Research 15 (11): 4067–4097. https://doi.org/10.1007/s13346-025-01908-7.

Harvard

Yang, S., Ta, Y. N. and Chen, Y. (2025) ‘Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities’, Drug Delivery and Translational Research, 15(11), pp. 4067–4097. doi:10.1007/s13346-025-01908-7.

IEEE

S. Yang, Y. N. Ta, and Y. Chen, “Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities,” Drug Delivery and Translational Research, vol. 15, no. 11, pp. 4067–4097, 2025, doi: 10.1007/s13346-025-01908-7.

BibTeX

@article{yang2025nanotechnology,
  title     = {{Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities}},
  author    = {Yang, Sheng and Ta, Yen‐Nhi Ngoc and Chen, Yunching},
  journal   = {Drug Delivery and Translational Research},
  year      = {2025},
  volume    = {15},
  number    = {11},
  pages     = {4067--4097},
  doi       = {10.1007/s13346-025-01908-7},
  url       = {https://doi.org/10.1007/s13346-025-01908-7}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research

  • pancreatic ductal adenocarcinoma
  • cancer immunotherapy
  • nanomedicine
  • tumor microenvironment
  • immunosuppression
  • tumor stroma
  • drug delivery
  • cancer vaccines

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Yang, S., Ta, Y. N., & Chen, Y. (2025). Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities. Drug Delivery and Translational Research, 15(11), 4067–4097. https://doi.org/10.1007/s13346-025-01908-7

How many times has this paper been cited?

19 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Drug Delivery and Translational Research: sign in and open the PDF from this page.

Who wrote this paper?

Sheng Yang, Yen‐Nhi Ngoc Ta, Yunching Chen.

What is the DOI of this paper?

10.1007/s13346-025-01908-7, permanently at https://doi.org/10.1007/s13346-025-01908-7. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.